patent.fyi
Applications  /  US 2026/0356806
United States Patent Application Publication

US 2026/0356806 A1

Published
Nov 12, 2026
Filed
Sep 28, 2023
Earliest date on the face
Sep 29, 2022
Classification
C07D 231/56
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Oxygen at the X position

What ifWhat if an endocyclic oxygen occupies the X position in a five-membered ring?
Claim language“X is —N— or —CRX—”

The oxygen forms two single bonds to its ring neighbors. The five-membered ring constrains the directions of the attached groups, and an oxygen lone pair provides a hydrogen-bond acceptor at X.

1.2Cyano substitution at X

What ifWhat if the carbon at X bears a cyano group?
Claim language“RX is hydrogen, halogen”

The nitrile carbon bonds directly to the ring carbon at X. The linear C≡N group projects a hydrogen-bond acceptor along the substituent axis and withdraws electron density from the ring.

1.4Thioether sulfur at Y

What ifWhat if a divalent thioether sulfur connects the two neighbors at Y?
Claim language“Y is —N—, —CRY—, or —C(═O)—”

Sulfur forms two single bonds to the neighboring carbons in the ring. Its longer carbon–sulfur bonds change the local ring geometry, and its polarizable electron density supports dispersion contacts in a binding pocket.

1.12Tetrazole at the terminal position

What ifWhat if a 1H-tetrazol-5-yl group occupies the R8 position and supplies the terminal acidic group?
Claim language“R8 is —C(═O)OR9”

The scaffold bonds directly to carbon 5 of the tetrazole. Deprotonation distributes negative charge over the ring nitrogens, providing an anionic site for electrostatic contact with a basic residue.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

TEAD inhibition in biomaterials testing

Seed fibroblasts carrying a TEAD-responsive luminescent reporter onto hydrogels of different stiffness coated with the same adhesion protein. Apply the inhibitor and its vehicle in separate wells at each stiffness. Divide reporter luminescence by viable cell count and compare inhibitor-treated wells with vehicle-treated wells at each stiffness to measure the TEAD-dependent contribution to the response.

Component substitution

Thioether replaces the ether linker

Replace the oxygen atom in an ether-linked member with sulfur at linker position L. Retain the attachment atoms on both sides of the linker so the thioether joins the same fragments as the ether. Prepare the thioether by reacting a thiol on one fragment with an alkyl halide on the other fragment. Compare the two compounds in a TEAD binding assay and measure aqueous solubility separately.

Parameter or scale variation

Miniaturized TEAD reporter concentration series

Run a cell-based TEAD reporter assay in 384-well plates at 40 microliters per well. Dose the inhibitor in duplicate at eight concentrations in a threefold dilution series starting at 10 micromolar, with 0.1 percent dimethyl sulfoxide in all test and vehicle wells. After 24 hours, measure reporter luminescence and use a parallel viability plate to identify concentrations that reduce viable cell count.

Combination with existing systems

TEAD binding by surface plasmon resonance

Immobilize a purified TEAD domain on one flow cell of a surface plasmon resonance sensor and use a second flow cell as a reference. Inject a concentration series of the inhibitor over both flow cells in solvent-matched running buffer. Subtract the reference and buffer responses, then fit the corrected equilibrium responses to estimate the dissociation constant.

Inhibitor washout in a perfused culture

Place cells carrying a TEAD-responsive reporter in a microfluidic chamber supplied by independently selectable vehicle and inhibitor reservoirs. Perfuse vehicle to establish the baseline, switch to inhibitor-containing medium for a defined exposure, then switch back to vehicle at the same flow rate. Image the reporter at fixed intervals and collect outlet samples for liquid chromatography with mass spectrometry to relate reporter recovery to compound clearance from the chamber.

Specific version of a part

Para methyl on phenyl

RX is a phenyl group that bonds to X through carbon 1. A methyl group at carbon 4 extends the hydrophobic surface along the phenyl ring's attachment axis.

Direct nitrile at Y

Y is a ring carbon bearing a directly attached cyano group. The terminal nitrogen provides a hydrogen-bond acceptor at the end of the linear C≡N unit.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0066424 A1
Published
Mar 6, 2014
Filed
Aug 23, 2013
Class
C07D 413/04
Document BUS 2022/0017566 A1
Published
Jan 20, 2022
Filed
Sep 23, 2019
Class
C07J 63/008
Claim 1
Document A
Document B
1.1X is —N— or —CRX—
1.2RX is hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
R1 is selected from the group consisting of —Y2-alkyl-N(R4)R5, hydrogen, deuterium, halogen, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, aminoalkyl, acyl, carboxylalkyl, carbonyl, carboxyl, cyano, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, oxo, alkylthio, thiolalkyl, mercaptyl, thiol, sulfonate, sulfonamido, alkylsulfonyl, amino, amido, alkylamino, dialkylamino, carbamate, nitro, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyloxy,
A · US 2014/0066424 A1 · ¶
1.3wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R
cycloalkylcarbonyl, arylcarbonyl, heterocycloalkylcarbonyl, heteroarylcarbonyl, cycloalkylalkyl, arylalkyl, heterocycloalkylalkyl, heterocycloalkylcarbonylalkyl, and heteroarylalkyl, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkenyl, alkynyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, amidoalkyl, acyl, carbonyl, carboxyl, carboxylalkyl, alkylcarbonyl, heteroalkyl
A · US 2014/0066424 A1 · ¶
Rx is hydrogen, —NO2, —CN, or —S(═O)2Ra; each R4 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R4a; each R4a is independently oxo, deuterium, halogen, —CN, —ORb, —NRcRd
B · US 2022/0017566 A1 · ¶
1.4Y is —N—, —CRY—, or —C(═O)—
1.5RY is hydrogen, halogen, —CN, —OH, —ORa, —NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
R3 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, haloalkyl, perhaloalkyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acyl, carbonyl, carboxyl, cyano, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, hydroxyalkoxy, oxo, alkylthio, mercaptyl, thiol, haloalkylthio, perhaloalkylthio, cyanoalkylthio, haloalkylsulfonyl, alkylsulfonyl, alkoxyalkylsulfonyl, cyanoalkylsulfonyl, sulfonate, sulfonamido, amino, amido, alkylami
A · US 2014/0066424 A1 · ¶
1.6wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R
1.7Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
E is selected from the group consisting of aryl and heteroaryl; G is selected from the group consisting of saturated 3- to 7-membered cycloalkyl and saturated 3- to 7-membered heterocycloalkyl;
A · US 2014/0066424 A1 · ¶
wherein: Ring A is a cycloalkyl or a heterocycloalkyl;
B · US 2022/0017566 A1 · ¶
1.8each R1 is independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SF5, —SH, —SRa, —S(═O)Ra, —S(═O)2R, —S(═O)2NRcRd, —S(═O)(═NRb)Rb, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(═O)R, —C(═O)ORb, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl)
R1 is hydrogen, deuterium, halogen, —CN, —ORb, —NRcRd, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, or C1-C6 heteroalkyl; each R2 is independently deuterium, halogen, —CN, —ORb, —NRcRd, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cy
B · US 2022/0017566 A1 · ¶
1.9wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R1a
1.10or two R1 on the same atom are taken together to form an oxo
1.11each R1a is independently halogen, —CN, —NO2, —OH, —ORa, —OC(—O)Ra, —OC(═O)ORa, —OC(═O)NRcRd, —SF5, —SH, —SRa, —S(—O)Ra, —S(—O)2Ra, —S(═O)2NRcRd, —S(═O)(═NR)R11, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(—O)Ra, —C(═O)OR, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
heterocycloalkylcarbonylalkyl, and heterocycloalkylcarbonyl, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkenyl, amidoalkyl, acyl, carboxylalkyl, hydroxyalkylcarbonyl, alkynylcarbonyl, heteroalkyl, hydroxyalkyl, alkoxyalkyl, carboxyl, cyano, hydroxy, alkoxy, oxo, sulfonamido, alkylsulfonyl, amino, amido, carbamate, dialkylamino, dialkylaminoalkyl, trisubstituted siloxy, cy
A · US 2014/0066424 A1 · ¶
Rx is hydrogen, —NO2, —CN, or —S(═O)2Ra; each R4 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three lea; each R4a is independently oxo, deuterium, halogen, —CN, —ORb, —NRcRd
B · US 2022/0017566 A1 · ¶
1.12wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or two R1a on the same atom are taken together to form an oxo n is 0, 1, 2, 3, or 4 L is absent, —O—, —S—, —NR2—, —C(R3)2—, —C(R3)2—C(R3)2—, —C(R3)═C(R3)—, —C(R3)2O—, —OC(R3)2—, —C(R3)2S—, —SC(R3)2—, —C(R3)2NR2—, or —NR2C(R3)2— R2 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R each R3 is independently hydrogen, halogen, —CN, —OH, —ORa, —NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R or two R3 on the same carbon are taken together to form an oxo or two R3 on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one or more R or two R3 on different carbons are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl each optionally substituted with one or more R R4, R5, R6, and R7 are each independently hydrogen, halogen, or C1-C6alkyl R8 is —C(═O)OR9, —C(═O)NR10R11, —C(═O)R9, —S(═O)2NR10R11, —S(═O)2R9, —S(═O)R9, —P(═O)(OR10)(OR11), or —B(OR10)(OR11) R9 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl) wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R9a each R9a is independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORa, —OC(═O)NRcRd, —SF5, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(O)2NRcRd, —S(═O)(═NRb)Ra, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORa, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(═O)Ra, —C(═O)ORa, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or two R11 on the same atom are taken together to form an oxo R10 and R11 are each independently hydrogen, —CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl) wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R10a or R10 and R11 are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R10b each R10a is independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRWRd, —SF5, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —S(═O)(═NRb)Rb, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORa, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or two R10a on the same atom are taken together to form an oxo each R10b is independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SF5, —SH, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —S(═O)(═NRW)Rb, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or two R10b on the same atom are taken together to form an oxo U is —C— or —N— T is —C— or —N— provided that U and T are not both —N— provided that U and T are both —C— when Ring B is a phenyl or 6-membered heteroaryl Ring B is a phenyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkyl, or C5-C7 cycloalkyl each R12 is independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SF5, —SH, —SRa, —S(═O)Ra, —S(═O)2R, —S(═O)2NRcRd, —S(═O)(═NRb)Rb, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —N═S(═O)(Rb)2, —C(═O)R, —C(═O)ORb, —C(═O)NRcRd, —P(═O)(Rb)2, C1-C6alkyl, Ce—C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or two R12 on the same atom are taken together to form an oxo or two R12 on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one or more R or two R12 on different atoms are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl each optionally substituted with one or more R m is 0, 1, 2, 3, 4, 5, or 6 or one R12 and RY are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl each optionally substituted with one or more R each R is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl) wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl) wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R Rc and Rd are each independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl) wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R each R is independently halogen, —CN, —OH, —SF5, —SH, —S(═O)C1-C3alkyl, —S(═O)2C1-C3alkyl, —S(═O)2NH2, —S(═O)2NHC1-C3alkyl, —S(═O)2N(C1-C3alkyl)2, —S(═O)(═NC1-C3alkyl)(C1-C3alkyl), —NH2, —NHC1-C3alkyl, —N(C1-C3alkyl)2, —N═S(═O)(C1-C3alkyl)2, —C(═O)C1-C3alkyl, —C(═O)OH, —C(═O)OC1-C3alkyl, —C(═O)NH2, —C(═O)NHC1-C3alkyl, —C(═O)N(C1-C3alkyl)2, —P(═O)(C1-C3alkyl)2, C1-C3alkyl, C1-C3alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl or two R on the same atom form an oxo provided that the compound is not
Y1 is alkyl, which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, and halogen; and Y2 is selected from the group consisting of a bond, carbonyl, alkylcarbonyl, carboxyl, oxy, thio, sulfinyl, sulfonyl, sulfonamido, amino, amido, alkylamino, and carbamate, any of which can be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, ha
A · US 2014/0066424 A1 · ¶
wherein: Ring B is a cycloalkyl or a heterocycloalkyl; each R14 is independently deuterium, halogen, —CN, —ORb, —NRcRd, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, or heterocycloalkyl; m is 0-6;
B · US 2022/0017566 A1 · ¶

An empty cell means only that no passage was reproduced there.

Statements in these documents
Methods to inhibit HIF pathway activity through the degradation of the HIFα protein subunits in a human or animal subject are also provided for the treatment of diseases mediated by HIF pathway activity.
A · US 2014/0066424 A1 · ¶ 2
HIF mediated survival of cells in hypoxia is a major contributor to resistance to therapies, lack of durable response and the foundation of residual disease.
A · US 2014/0066424 A1 · ¶ 8
The anti-inflammatory and anti-proliferative activity of the naturally occurring triterpenoid, oleanolic acid, has been improved by chemical modifications.
B · US 2022/0017566 A1 · ¶ 3
Compounds derived from oleanolic acid have been shown to affect the function of multiple protein targets and thereby modulate the activity of several important cellular signaling pathways related to oxidative stress, cell cycle control, and inflammation.
B · US 2022/0017566 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356806 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356806/, SHA-256 4773ee7a761fce98e2286634e4a6b601d2d2f49366c0f84a94ee748ebf0bffa0
First published
Permanent addresshttps://patent.fyi/US20260356806/
Content fingerprint (SHA-256)4773ee7a761fce98e2286634e4a6b601d2d2f49366c0f84a94ee748ebf0bffa0
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi